Effect of addition of pemafibrate and double dose of statin on small dense LDL cholesterol in statin-treated patients with type 2 diabetes and hypertriglyceridemia: A comparative Study.
- Conditions
- Hypertriglyceridemia
- Registration Number
- JPRN-jRCTs031190232
- Lead Sponsor
- Mori Yusaku
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 102
1. Age>=20 years old
2. Type 2 diabetes patients
3. Patients who have been taking below statins for 3 months or longer without changing
Atorvastatin 5, 10 mg/day
Pitavastatin 1, 2 mg/day
Rosuvastatin 2.5 mg/day
4. 150mg/dL=5. Written informed consent
1. Type 1 diabetes patients
2. 160mg/dL=3. Patients taking cyclosporine, rifampicin, PCSK9 inhibitors, MTP inhibitors
4. HbA1c>=10% within three months prior to informed consent
5. familial hypercholesteremia
6. Patients taking statins other than those specified in the inclusion criteria
7. Patients taking statins other than those prescribed by the inclusion criteria
8. Patients who have taken SPPARM alpha or fibrates within three months prior to informed consent
9. Patients who have changed prescriptions for dyslipidemia * and diabetes <*Ezetimibe (including compounding agents), anion exchange resin, ethyl icosapentate (including supplements), ethyl omega-3 fatty acid (including supplements)> within three months prior to informed consent
10. Patients receiving pemafibrate
11. 1.5mg/dL=12. Alcoholics patients (or alcohol abuse patients)
13. Patients who have developed diabetic ketoacidosis within three months prior to informed consent
14. Patients with active malignant tumor, autoimmune disease, infectious disease
15. Any other patients regarded unsuitable by the principal investigator or sub-investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method